These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37787330)

  • 1. Prolonged response to Tyrosine Kinase Inhibitors followed by Immunotherapy in metastatic hepatocellular carcinoma: A rare case report.
    Roy P; Parthasarathy KM
    J Cancer Res Ther; 2023; 19(5):1457-1461. PubMed ID: 37787330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
    Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
    J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
    Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC
    Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
    Yau T; Park JW; Finn RS; Cheng AL; Mathurin P; Edeline J; Kudo M; Harding JJ; Merle P; Rosmorduc O; Wyrwicz L; Schott E; Choo SP; Kelley RK; Sieghart W; Assenat E; Zaucha R; Furuse J; Abou-Alfa GK; El-Khoueiry AB; Melero I; Begic D; Chen G; Neely J; Wisniewski T; Tschaika M; Sangro B
    Lancet Oncol; 2022 Jan; 23(1):77-90. PubMed ID: 34914889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
    Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
    BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review.
    Kim TS; Kim JH; Kim BH; Lee YS; Yoo YJ; Kang SH; Suh SJ; Jung YK; Seo YS; Yim HJ; Yeon JE; Byun KS
    Clin Mol Hepatol; 2017 Dec; 23(4):340-346. PubMed ID: 28633200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma.
    Kim Y; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Goh MJ; Kang W; Kim SU
    Eur J Gastroenterol Hepatol; 2023 Feb; 35(2):191-197. PubMed ID: 36574310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the immunotherapy roadmap for hepatocellular carcinoma.
    Baretti M; Kim AK; Anders RA
    Cancer Cell; 2022 Mar; 40(3):252-254. PubMed ID: 35290785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.
    Hur MH; Cho Y; Kim DY; Lee JS; Kim GM; Kim HC; Sinn DH; Hyun D; Lee HA; Seo YS; Lee IJ; Park JW; Kim YJ
    Clin Mol Hepatol; 2023 Jul; 29(3):763-778. PubMed ID: 37254488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
    Yang S; Zhou Y; Zeng L
    Adv Clin Exp Med; 2023 Aug; 32(8):839-845. PubMed ID: 37140014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
    Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
    Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.